.

Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia

LAUR Repository

Show simple item record

dc.contributor.author Kabbara, Wissam K.
dc.contributor.author Ramadan, Wijdan H.
dc.contributor.author Rahbany, Peggy
dc.contributor.author Al-Natour, Souhaila
dc.date.accessioned 2016-10-03T06:41:42Z
dc.date.available 2016-10-03T06:41:42Z
dc.date.copyright 2015 en_US
dc.date.issued 2016-10-03
dc.identifier.issn 1176-6336 en_US
dc.identifier.uri http://hdl.handle.net/10725/4481
dc.description.abstract Background: Fluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged. Objective: The primary objective of the study was to evaluate the appropriate use of commonly prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in renal impairment, and duration of treatment. The secondary objective was to investigate the dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic and nondiabetic patients. Methods: A prospective observational study at a teaching hospital in Lebanon was conducted over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones (levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited from internal medicine floors and intensive care units. Results: The final percentage for the appropriate indication, dose, and duration of fluoroquinolone therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients did not receive the appropriate dose adjustment according to their level of renal impairment. In addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin (7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highest incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin (39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%). Conclusion: The major clinical interventions for the future will adjust the dose and duration of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was less common than hyperglycemia. en_US
dc.language.iso en en_US
dc.title Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200104485 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal Therapeutics and Clinical Risk Management en_US
dc.journal.volume 2015 en_US
dc.journal.issue 11 en_US
dc.article.pages 639-647 en_US
dc.keywords Fluoroquinolones en_US
dc.keywords Ciprofloxacin en_US
dc.keywords Levofloxacin en_US
dc.keywords Moxifloxacin en_US
dc.keywords Dysglycemia en_US
dc.identifier.doi https://doi.org/10.2147/TCRM.S81280 en_US
dc.identifier.ctation Kabbara, W. K., Ramadan, W. H., Rahbany, P., & Al-Natour, S. (2015). Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia. Therapeutics and clinical risk management, 11, 639-647. en_US
dc.author.email wissam.kabbara@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410896/ en_US
dc.orcid.id https://orcid.org/0000-0002-7310-9192 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account